Editas Medicine (EDIT) Net Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has reported Net Cash Flow for 11 consecutive years, with $25.9 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Cash Flow fell 17.5% year-over-year to $25.9 million; the TTM figure through Dec 2025 stood at $32.9 million (up 317.04% YoY), while the FY2024 annual figure was $7.9 million, up 144.15% from the prior year.
• Net Cash Flow improved to $25.9 million in Q3 2025 per EDIT's latest filing, from -$150000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $215.2 million in Q1 2021 and bottomed at -$138.3 million in Q3 2023.
• Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of -$150000.0 in 2025.
• Annual changes were most pronounced in 2021 — Net Cash Flow soared 4804.61% — and 2023, when it plunged 434.79%.
• Editas Medicine's Net Cash Flow stood at -$56.4 million in 2021, then declined by 22.74% to -$69.2 million in 2022, then surged by 159.43% to $41.1 million in 2023, then slipped by 13.15% to $35.7 million in 2024, then fell by 27.47% to $25.9 million in 2025.
• Business Quant data shows EDIT's Net Cash Flow at $25.9 million in Q3 2025, -$150000.0 in Q2 2025, and $7.2 million in Q1 2025.